After sitting through the full presentation on the Phase 3 INTerpath-001 trial at the ESMO Congress over the weekend, ...

Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a privately held company and developer of the FiberLocker ® System.

TriKE ® is a registered trademark owned by GT Biopharma, Inc.

First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028. Built ...

The Comeback Club connects people who have had joint replacement with those considering it. ATLANTA and WARSAW, Ind., Oct. 26, 2026 /PRNewswire/ -- The Arthritis Foundation today announced the launch ...

TTX-MC138 was administered once every 28 days across four evaluated dose levels ranging from 0.8 mg/kg to 4.8 mg/kg. The study met its primary safety endpoint, and no dose-limiting toxicities were ...

The Study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group comparative study in pregnant women ...

Nasdaq closes the minimum bid price matter confirming that the Company has regained compliance. PHILADELPHIA, Oct. 26, 2026 ...

Presentation will introduce ART26.12, the first selective FABP5 inhibitor to enter human clinical studies, to the world’s largest gathering of pain professionals. Growing body o ...

Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and ...

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing small molecule therapeutics ...

Active LN patients in the Phase 1 study treated with FT819 and the less-intensive conditioning (bendamustine) regimen selected for the RECLAIM-LN study achieved 100% renal response at Month 6, with ...